MLYS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Mineralys Therapeutics Inc (MLYS) presents a strong long-term investment opportunity for a beginner investor with $50,000-$100,000 available for investment. Despite short-term technical weakness, the significant upside potential of 114.78% based on analyst targets, hedge fund buying activity, and promising clinical developments for its lead drug lorundrostat make this a compelling buy.
The technical indicators suggest a bearish short-term trend. The MACD is below zero and negatively contracting, RSI is neutral at 38.702, and moving averages show a bearish alignment (SMA_200 > SMA_20 > SMA_5). The stock is currently trading near its support level (S1: 22.742).
Analysts have raised the price target to $51, citing underappreciated peak sales potential for lorundrostat.
Hedge funds are significantly increasing their positions, with a 516.79% increase in buying over the last quarter.
The stock has a potential upside of 114.78% based on current price and analyst target.
Weak financial performance in Q4 2025, with net income dropping by 34.14% YoY and EPS declining by 59.18%.
Short-term technical indicators are bearish, suggesting potential near-term price weakness.
In Q4 2025, the company reported no revenue growth (0% YoY), a net income loss of -$32.23M (down 34.14% YoY), and a significant EPS decline of 59.18%. Gross margin remained at 0%.
Analysts are bullish, with BofA raising the price target to $51 from $46 and maintaining a Buy rating. They believe the peak sales opportunity for lorundrostat is underappreciated, signaling confidence in the company's future growth.
